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1. Introduction 
1.1. Special subtypes of invasive breast carcinoma 
1.1.1. Morphological classification of invasive breast carcinoma 
Breast carcinoma has been traditionally classified into different subtypes based on its 
morphological features. The most common type of breast cancer, the previously 
called “invasive ductal carcinoma” is in fact not a particular tumor type. It has been 
re-named in the latest edition of the “WHO classification of the tumours of the breast” 
(2012) as invasive breast carcinoma of no special type (NST) emphasising its lack of 
particular morphological features and its extremely heterogeneous appearance 
(Lakhani et al. 2012). Invasive carcinoma NST constitutes approximately 75% to 80% 
of all invasive breast carcinomas [(Lakhani et al 2012), (Rosen 2009), (Tulinius et al. 
1988)]. The remaining breast cancers belong to the so-called “special subtypes”. 
These constitute a long list with the most common subtype being invasive lobular 
carcinoma, and the rest including tumors such as invasive tubular carcinoma, 
metaplastic carcinoma, and invasive micropapillary carcinoma among others 
(Lakhani et al. 2012). A complete list of the special subtypes of breast carcinoma 
according to the WHO is included in List 1.  
List 1: WHO classification of tumors of the breast (Lakhani et al. 2012) 
 
Invasive carcinoma of no special type (NST) 
  Pleomorphic carcinoma 
  Carcinoma with osteoclast-like stromal giant cells 
  Carcinoma with choriocarcinomatous features 
Special subtypes 
Invasive lobular carcinoma  
Classic lobular carcinoma  
Solid lobular carcinoma 
Alveolar lobular carcinoma 
Pleomorphic lobular carcinoma  
Tubulolobular carcinoma 
Mixed lobular carcinoma 
 Tubular carcinoma 
 Cribriform carcinoma 
 Mucinous carcinoma 
Carcinoma with medullary features  
Medullary carcinoma 
 Atypical medullary carcinoma 
Invasive carcinoma NST with medullary features 
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 Carcinoma with apocrine differentiation 
 Carcinoma with signet ring cell differentiation 
 Invasive micropapillary carcinoma 
 Metaplastic carcinoma of no special type 
   Low-grade adenosquamous carcinoma 
   Fibromatosis-like metaplastic carcinoma 
   Squamous cell carcinoma 
   Spindle cell carcinoma 
Metaplastic carcinoma with mesenchymal differentiation  
Chondroid differentiation 
Osseous differentiation 
Other types of mesenchymal differentiation 
 Mixed metaplastic carcinoma 
 Myoepithelial carcinoma 
Rare types 
 Carcinoma with neuroendocrine features 
   Neuroendocrine tumor, well differentiated 
Neuroendocrine carcinoma, poorly differentiated (small cell 
carcinoma) 
   Carcinoma with neuroendocrine differentiation 
 Secretory carcinoma 
 Invasive papillary carcinoma 
 Acinic cell carcinoma 
Mucoepidermoid carcinoma 
Polymorphous carcinoma 
Oncocytic carcinoma 
Lipid-rich carcinoma 
Glycogen-rich clear cell carcinoma 
Sebaceous carcinoma 
Salivary gland/skin adnexal type tumors 
   Cylindroma  
Clear cell hydradenoma 
1.1.2. Significance of the special subtype 
Identification of special subtypes of breast carcinoma has been traditionally used as a 
tool to refine the prediction of behaviour and response to therapy in breast cancer 
provided by other morphologic prognostic parameters such as tumor grade, tumor 
size, lymph node status and lymphovascular invasion [(Carry et al. 2005), (De 
Mascarel 2008), (Ellis et al. 1992), (Jeruss et al. 2008), (Michaelson et al. 2003), 
Perry et al. 2008), (Rakha et al. 2008), (Tabar et al. 1996), (Vinh-Hung et al. 2003)]. 
Breast carcinoma subtypes have a characteristic morphology that typically correlates 
with a specific clinical behaviour. For example, colloid, tubular, and cribriform 
carcinomas, in their pure form (i.e. >90% of the tumor volume is composed of the 
special type) have a very good prognosis in comparison to invasive carcinoma NST 
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presenting at a similar pathologic stage [(Carstens et al. 1985), (Clayton 1986), 
(Fischer et al. 1980)]. Moreover, these types present usually at an early with negative 
or low count of positive lymph nodes (≤3) (Donegan 1997). Carcinomas with special 
morphology can be admixed with the invasive breast carcinoma NST. When the 
special pattern constitutes 50-90% of the tumor volume, the tumor is then termed 
mixed carcinoma NST and special type, for example “mixed invasive breast 
carcinoma NST and tubular carcinoma” (Lakhani et al. 2012). In this case the tumor 
loses some of its “special” behavioural characteristics as compared to the pure 
special subtype [(Norris et al 1965), (Page et al.1983)]. 
Other special morphologies do not confer to the tumor a different prognosis than that 
of invasive carcinoma NST -or at least the difference in prognosis is debatable-, but 
show a different type of presentation and behaviour. Invasive lobular carcinoma is a 
good example in this case [(Ashikari et al. 1973), (Cha et al. 2014), (Silverstein et al. 
1994)]. It presents more often than other types as a bilateral or a multifocal tumor 
with a diffuse pattern of infiltration and therefore requires different pre-operative 
studies than invasive carcinoma NST to detect its extent [(Berg et al. 2004), (Chung 
et al. 1997), (Pestalozzi et al. 2008)]. In this case Magnetic Resonance Imaging 
(MRI) is more accurate than mammography and sonography and is used in the 
assessment of the preoperative extent of the disease and staging of the patients [ 
(Kepple et al. 2005), (Mann et al. 2008)]. Moreover, the pattern of metastasis of 
invasive lobular carcinoma is different than that of breast carcinoma NST. The former 
has a higher affinity for visceral organs, bone, meninges, ovaries and serosal tissue 
[(Borst et al. 1993), (Dixon et al. 1991), (Harris et al. 1984), (Lamovec et al. 1991)].  
In other cases the specific morphology when present indicates a worse clinical 
behaviour than that of invasive carcinoma NST. This is the case of invasive 
micropapillary carcinoma (IMPCa), which is the focus of this study. 
1.2. Special subtypes vs. intrinsic subtypes of invasive breast carcinoma  
1.2.1. Definition and classification of the intrinsic molecular subtypes 
It is noteworthy that one of the most important prognostic factors that have emerged 
in the past few years is the molecular typing of breast cancer (Perou et al. 2000). 
Based on the molecular gene expression profiles and with the use of 
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immunohistochemical correlates, “intrinsic subtypes” of breast cancer have been 
identified [(Goldhirsch et al. 2013), (Goldhirsch et al. 2011), (Maisonneuve et al. 
2014)]. These have important therapeutic consequences and prognostic implications 
(Goldhirsch et al. 2013). 1) Luminal A and 2) Luminal B subtypes are hormone 
receptor positive, 3) HER2 subtype is hormone receptor negative but HER2 positive, 
and 4) Triple negative subtype is hormone receptor and HER2 negative. Luminal B 
differs from Luminal A by a lower value of PR and/or a higher Ki67 proliferation index. 
Luminal B can be HER2 negative or positive (in addition to being hormone receptor 
positive). A detailed classification of the intrinsic subtypes according to the St-Gallen 
Consensus Conference 2013 is included in Table 1.  
Table 1: Surrogate definition of intrinsic subtypes of breast cancer  
Intrinsic subtype Clinicopathologic surrogate definition 
Luminal A Luminal A-like: ER and PR+, HER2 –, Ki67 ‘low’ 
Luminal B Luminal B-like HER2 negative: ER +, HER2- and at least one 
of: Ki67 ‘high’, PR – or ‘low’, 
Luminal B-like HER2 positive: ER+, HER2+, any Ki67, any PR 
Erb-B2 overexpression HER2: HER2 + and ER/PR - 
Basal-like Triple negative (ductal): ER, PR and HER2- 
Notes: 1) The cut-point between ‘high’ and ‘low’ values for Ki-67 varies between 
laboratories. A level of <14% best correlated with the gene-expression definition of Luminal A 
based on the results in a single reference laboratory. Some of the participants preferred to 
use a cut off value of 20%. 2) A cut-point of <20% was used to characterise the “low” PR 
values. 
1.2.2. Significance of the intrinsic molecular subtypes 
The classification of breast carcinoma into one of the four molecular subtypes is very 
important since each of these subtypes responds to a different targeted therapy 
[(Goldhirsch et al. 2013), (Goldhirsch et al. 2011)]. Endocrine therapy is used for the 
Luminal A subtype. The case of the Luminal B tumors is more complicated. These 
are treated with chemotherapy in addition to endocrine therapy and with HER2 
targeted therapy when they are HER2 positive. Chemotherapy alone is usually 
administered in the case of triple negative breast cancer. For the HER2 positive 
subtype, chemotherapy is recommended in addition to HER2 targeted therapy 
(Goldhirsch et al. 2013).  
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1.2.3. Intrinsic molecular subtypes in relation to special subtypes  
Although the molecular classification seems to have overshadowed the 
morphological classification and the traditional prognostic markers in breast cancer, 
the latter still have their importance. Moreover, there is a strong correlation between 
the special subtypes and the intrinsic molecular subtypes of breast cancer 
[(Caldarella et al. 2013), (Weigelt et al. 2008)]. For example, invasive lobular 
carcinoma belongs almost always to the Luminal subtype, so do tubular, cribriform 
and mucinous carcinomas [(Colleoni et al 2012), (Jung et al. 2010)]. Metaplastic 
carcinoma, carcinoma with medullary features and adenoid cystic carcinoma are 
overwhelmingly triple negative tumors (Reyes et al. 2013). However, despite their 
belonging to the same molecular type these tumors display different clinical 
behaviour and prognosis. Invasive lobular carcinoma has a worse behaviour 
compared to that of invasive tubular or invasive cribriform carcinoma. Adenoid cystic 
carcinoma of the breast, although triple negative, has an excellent prognosis with 
extremely rare metastatic potential, very different from that of the metaplastic 
carcinoma and carcinoma with medullary features [(Irshad et al 2011), (Montagna et 
al. 2013)]. In these cases tumor morphology conveys crucial information in addition to 
the molecular subtyping in regard to prognosis and therapy.  
Therefore, despite the groundbreaking molecular advances in breast cancer, a 
careful study of the traditional characteristics of the tumor including morphology and 
the classification of breast cancer into one of the special subtypes or no special type 
(NST) remains necessary (Dieci et al. 2014). It remains also important to understand 
why a particular morphology confers to the tumor a particular behaviour.  
1.3. Next generation sequencing (NGS) in the different types of invasive breast 
carcinoma  
As cancer is a genetic disease driven by hereditary or somatic mutations, DNA 
sequencing is crucial in discovering these mutations. In recent years NGS 
technologies also called second- generation technologies have played a major role in 
understanding the altered genetic pathways involved in cancer. In comparison to 
earlier sequencing methodologies (Sanger sequencing), NGS is a high throughput 
method allowing in a relatively short time and at a relatively low cost massively to 
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parallel sequence millions of DNA templates. This can offer eventually a major 
advantage in terms of rapid diagnosis and the choice of targeted therapy when 
available.   
Practically, there are multiple NGS platforms available, mainly from three companies 
(Roche, Illumina, and Life Technologies), differing by sequencing chemistry and 
methods for signal detection [(Chin et al 2011), (Meldrum et al. 2011)]. DNA 
sequencing includes whole-genome sequencing (WGS), whole-exome sequencing 
(WES), and gene-panel sequencing. Although mostly used for basic and clinical 
research, NGS is not only limited to this field. It is being increasingly useful in clinical 
practice mainly in solid tumors, where the detection of certain genetic mutations has 
a major impact on therapy.  
A limited numbers of studies have been published to date on the application and 
utility of NGS in breast cancer. For an extensive overview we refer to the paper by 
Desmedt et al, which reviews the results of the largest four studies addressing this 
topic (Desmedt et al. 2012). In summary, these papers show that with the use of 
NGS new driver breast cancer genes are identified, those however being infrequent 
(<10% of the cases) compared to p53 and PIK3CA genes (>30% of the cases of ER 
negative and ER positive breast carcinomas respectively). On the other hand not all 
breast cancers harbour a driver mutation suggesting that other mechanisms such as 
DNA methylation can be involved in the pathogenesis of this disease. These studies 
also show that gene mutations are very heterogeneous in breast cancer but these 
however belong to a limited number of genetic pathways, a finding that can have 
major consequences on breast cancer targeted therapy. Lastly, they demonstrate 
that some mutations might be associated to the response or resistance to anticancer 
therapies.  
In later studies, other researchers have shown that specific genetic alterations 
detected by NGS can be linked to specific breast cancer phenotypes (Russnes et al. 
2011). For example breast cancer subtypes such as lobular and medullary 
carcinomas that are ER positive/HER2 negative and ER negative/HER2 negative 
respectively and belong to luminal A (lobular carcinoma) and basal-like (medullary 
carcinoma) molecular subtypes. In a further step recent NGS studies demonstrate 
that these two carcinoma subtypes also display different classes of mutations. To 
14 
 
date there is no data in the literature on NGS in invasive micropapillary breast 
carcinoma.  The technique appears however to be very promising in explaining the 
morphology of this type of breast cancer and its behavior, which are very unique as it 
is detailed later. 
1. 4. A special subtype of invasive breast carcinoma: Invasive micropapillary 
carcinoma  
1.4.1. Historical perspective and terminology  
The special subtype of IMPCa, as it is described in the next paragraph, have been 
first noticed in the 1980s by Fischer et al. who described this particular tumor 
configuration as “exfoliative” appearance and referred to these tumors as “pseudo 
papillary carcinoma” (Fischer et al. 1980). The name “Invasive micropapillary 
carcinoma” was first given in 1993 by Tavassoli et al. The authors described nine 
cases of breast carcinoma with this morphology and demonstrated the aggressive 
behaviour of the tumor (Siriaunkgul and Tavassoli 1993). In 1994 Luna-Moré et al 
proposed the recognition of IMPCa as a new entity (Luna-Moré et al. 1994). This 
term was officially recognised in 2003 in the 3rd edition of the WHO classification of 
tumors “Pathology and genetics of the Tumours of the Breast and the Female Genital 
Organs” (Tavassoli and Devilee 2003). 
1.4.2. Description of the morphological features  
The typical morphology of IMPCa consists of groups of breast cancer cells which are 
lacking, by definition, fibrovascular cores (as opposed to the term papillary), and are 
surrounded by clear spaces. Some authors believe these spaces are artefact of 
fixation (Tressera et al. 1999). In any case, although they resemble lymphatic 
channels they lack however endothelial cells as it was demonstrated by 
immunohistochemical staining [(Siriaunkgul and Tavassoli 1993), (De La Cruz et al. 
2004), (Pettinato et al. 2004)]. The surrounding stroma shows no desmoplastic 
reaction but is typically described as “spongy” where thin strands of fibrous tissue 
separate the groups of tumor cells (Luna-More et al 1994). The mitotic rate and the 
cellular morphology are variable with moderate cellular atypia (Figure 1). Psammoma 
bodies have been described  in  almost half of the cases (42–62%) [(Middleton et al. 
1999), (Pettinato et al. 2004)]. 
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Defined as such, a pure invasive micropapillary growth pattern is rarely observed 
This pattern is usually mixed, in variable proportion, with invasive breast carcinoma 
NST or less commonly with other special subtypes of breast carcinoma [(Luna-More 
et al. 1994), (Walsh and Bleiweiss 2001)] (Figure 2). It has been also shown that 
most often, tumors with IMPCa retain the micropapillary growth pattern in 
lymphovascular spaces, as well as in lymph nodes and systemic metastases (Walsh 
and Bleiweiss 2001)  (Figure 3). 
 
 
 
 
 
Figure 1: Invasive micropapillary carcinoma of the breast on a H&E section, low (left) and 
high magnifications (right) 
 
Figure 2: Invasive micropapillary carcinoma (right and upper part) of the breast admixed with 
invasive carcinoma no special type (left and lower part) at low magnification. 
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Figure 3: Invasive micropapillary carcinoma in metastatic sites; the invasive micropapillary 
morphology is preserved in lymph nodes (picture to the left) and in lymphovascular spaces 
(picture to the right), both at low magnification. 
 
1. 5. IMPCa in organs other than breast 
1.5.1. General information 
Tumors with micropapillary morphology, although initially described in breast, occur 
in other organs such as the genitourinary tract, lung, gastrointestinal tract and 
salivary glands. In every organ system, these tumors have a marked propensity for 
lymphatic metastasis and an aggressive behaviour when compared to conventional 
carcinomas arising in these organs [ (Amin and Epstein 2012), ( Amin et al. 1994), ( 
Amin et al. 2002), (Khayyata et al. 2005), (Sakamoto et al. 2005), (Shimoda et al. 
2008)].  
1.5.2. IMPCa of the genitourinary tract 
This tumor occurs most commonly in the bladder where two distinct morphologic 
patterns of micropapillary carcinoma have been described: 1) an invasive pattern with 
the classic micropapillary morphology as described above and 2) a non-invasive 
component formed by slender filiform projections with or without thin fibrovascular 
cores resembling more the micropapillary serous carcinoma of the ovary [(Alvarado-
Cabrero et al. 2004), (Amin and Epstein 2012), (Amin et al. 1994), (Johansson et al. 
1999), (Loperz-Beltran et al. 2010), (Maranchie et al. 2000)]. In the bladder, IMPCa, 
same as in the breast, is almost always mixed with more conventional carcinoma, 
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papillary, invasive urothelial or adenocarcinoma and forms at least 20% of the tumor 
in most of the reported cases.  
IMPCa of the bladder, even when present as a focal component is an aggressive 
tumor with a high frequency of lymphovascular invasion and muscle invasion at 
presentation (Compérat et al 2010).  In general the outcome is poor [(Amin and 
Epstein 2012), (Watts and Hansel 2010)]. Therefore there is a tendency to treat this 
tumor with radical cystectomy even at an early stage (Willis et al. 2014). This has 
been however controversial [(Porten et al. 2014), (Wang and Wang 2013), (Willis et 
al. 2014)].  
Few cases have been reported in the ureters with similar morphology and outcome 
as in the bladder (Radulović et al. 2012).  
 
1.5.3. IMPCa of the lung 
In the latest International Association for the Study of Lung Cancer (IASLC)/American 
Thoracic Society (ATS)/European Respiratory Society (ERS) classification system of 
lung tumors (2011), micropapillary predominant carcinoma is recognised as an 
independent subtype of adenocarcinoma (Travis et al. 2011). This inclusion was 
justified by the poor prognosis of this tumor documented in earlier reports even in 
resected stage I patients (Travis et al. 2011). In a recent study, Hung et al. show that 
micropapillary predominant adenocarcinoma had a higher recurrence rate with a 
higher frequency of developing extrathoracic-only recurrences in comparison with the 
other subtypes of lung adenocarcinoma (except for the solid predominant 
adenocarcinoma subtype which showed similar behaviour as invasive micropapillary 
carcinoma). In addition, the micropapillary subtype was a significant negative 
prognostic factor in overall survival, and disease specific survival (Hung et al. 2014).  
Similar findings were obtained by Cha et al. who showed that micropapillary (and 
solid) subtype is common in tumors greater than stage I. In their study, the presence 
of the micropapillary subtype was a single prognostic factor for overall survival (Cha 
et al. 2014). 
Interestingly, IMPCa seems to grow as in the lung like in bladder in two different 
patterns which can be admixed: a common alveolar pattern where the tumor cells 
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float in alveolar spaces and a much less common stromal pattern where the IMPCa 
resembles that seen in breast (Ohe et al. 2012). On Univariate analysis both 
micropapillary patterns (alveolar and stromal) were significant predictors of 
unfavorable outcome. However, in multivariate analysis, among patients with stage I 
disease, patients with stromal but not alveolar micropapillary pattern showed a 
significantly poorer disease free survival than those without a micropapillary 
component (Ohe et al. 2012).  
1.5.4. IMPCa of the gastrointestinal tract 
IMPCa has been described in the colon, rectum, and stomach and less frequently in 
other locations such as the pancreatobiliary region. It is very rarely observed as a 
pure tumor or even as the predominant growth pattern in the tumor. Despite this 
observation, micropapillary morphology is associated in colorectal tumors with 
aggressive behaviour as demonstrated by a high frequency of lymphovascular 
invasion and lymph node metastases even in pT1 tumors. Stage I and II patients 
experience shorter survival as compared to the non-micropapillary groups (Guzińska-
Ustymowicz et al. 2014). In many of these cases the micropapillary histology is pure 
or predominant in the metastases even though it does not constitute the predominant 
component in the primary tumor [(Kim et al. 2006), (Sakamoto et al. 2005), (Wen et 
al. 2008)]. In the colorectum 50% of the cases are diagnosed in the ascending colon 
whereas tumors in the rectum are limited to case reports.  
This lesion is also rare in the stomach. In this organ, It has never been described as 
a pure tumor, however even a minor micropapillary component indicates tumor 
aggressiveness [(Eom et al. 2011), (Roh et al. 2010), (Ushiku et al. 2011)]. In the 
majority of cases, same as in the colon, there is lymphovascular invasion, lymph 
node metastases and an extension to the subserosa or to adjacent organs. Patients 
with IMPCa in the stomach have lower survival rates than those without a 
micropapillary component. It is still debatable whether or not the micropapillary 
morphology is an independent prognostic factor [(Ninomiya et al. 2013), (Roh et al. 
2010)].  
Khayyata et al found IMPCa in 4.1% of all cancers in ampullopancreatobiliary region, 
with the majority observed in the periampullary region (11% of all cancers in this 
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location), and the remaining in the pancreas (3% of pancreatic cancers) (Khayyata et 
al. 2005). Contrary to other locations, in the pancreas there was in association with 
the micropapillae an abundant inflammatory infiltrate composed mostly of neutrophils 
and less frequently of eosinophils that formed focal intraepithelial and stromal 
microabcesses (Khayyata et al. 2005). In most cases, local lymph node involvement 
was found [(Fujita et al. 2010), (Kitagawa et al. 2007)]. The same results regarding 
behaviour and patient outcome were observed in tumors arising in this location as in 
the colon and stomach, the number of cases is however very small (Khayyata et al. 
2005).  
1.5.5. IMPCa of the salivary glands  
Rare cases of tumors with IMPCa component have also been reported in other 
organs such as salivary glands in association with salivary duct carcinoma [(Michal et 
al. 2000), (Nagao et al. 2004), (Yamamoto et al. 2008)]. They have been described in 
the parotid and the submandibular gland. In one series all patients had 
lymphovascular and perineural invasion as well as lymph node metastases and most 
patients died of disease shortly after diagnosis (Nagao et al. 2004).  
1.6. Theories regarding the pathogenesis of IMPCa  
1.6.1. The theory of “the inside out pattern” or reverse polarity 
As we previously stated in our review article about IMPCa in the journal Advances in 
Anatomic Pathology (Nassar H. 2004):  “It is believed that the morphology of IMPCa 
is due to a reverse of the polarity of the neoplastic cells where the stroma-facing 
surface (basal surface) of the cells acquires apical secretory properties (Luna-More 
et al. 1994). Peterson described this phenomenon as an inside-out growth pattern 
(Peterson 1993). This alteration in cell polarity was demonstrated by electron 
microscopic examination of a handful of cases showing the presence of a large 
number of microvilli at the surface of the neoplastic cells facing the stroma, a finding 
that usually characterises the luminal surface of benign glands (Luna-More et al. 
1994)”.  At the molecular level we have demonstrated that proteins that are normally 
localised at the apical surface of glandular epithelial cells such as MUC1 are also 
abnormally expressed in IMPCa, a topic that we will detail next.  
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1.6.2. MUC1 glycoprotein and other molecules involved in polarity 
Epithelial cells are highly polarized and the establishment and maintenance of this 
polarity is crucial to their function. The mechanisms that induce and are involved in 
maintaining this polarisation are very complex and controlled by multiple pathways. 
These pathways include a large number of molecules involved in protein to protein 
interactions. It is believed that proteins involved in apical polarity are different than 
those involved in basolateral polarity and that these play an antagonistic role in order 
for polarity to be maintained. In addition the orientation of the epithelial cellular 
polarity depends to high extent on the extracellular matrix (Yu et al. 2005). Studies of 
the apical domain have focused on two major complexes: the Crumbs complex and 
the PAR complex (Macara 2004). PARD3, PARD6, and atypical protein kinase C 
(aPKC) form a PAR complex that localizes to the apical TJs junctions and regulates 
apical junction formation. Other important molecules, a lipid phosphatase (PTEN) and 
a small GTPase (Cdc42) among others are also involved in this complex mechanism 
of epithelial polarisation. The end result of this polarisation is the localisation of 
specific molecules in specific cellular domains where they achieve their function. 
Among these are mucins or MUCs which are a heterogeneous group of highly 
glycosylated proteins constituting the major component of mucus [(Corfield 2001), 
(Gendler 2001)]. This family of proteins can be divided into transmembrane and 
secretory mucins. Transmembrane mucins are believed to regulate growth, adhesion, 
and motility of the cells [(De La Cruz et al. 2004), (Ringel and Lohr 2003), (Taylor-
Papadimitriou et al. 2002)]. Among these is MUC1, or epithelial membrane antigen 
(EMA), expressed on the apical surface of normal glands in many tissues where it is 
believed to maintain lumen intergrity (Walker 1990).  
MUC1 loses its normal apical location in cancer and localizes mostly to the cytoplasm 
as can be demonstrated by immunohistochemical studies. Aberrant MUC1 
expression is associated with poor outcome [(Ceriani et al. 1992), (Hilkens et al. 
1995), (Muir et al. 1991), (Ohuchi et al. 1995), (Rahn et al. 2001), (Walker 1990)]. In 
IMPCa, we described another aberrant expression of MUC1; it is consistently 
expressed on the stroma-facing surface of the cell, independent of the location of the 
tumor (Nassar et al. 2004). This finding could explain the characteristic morphology 
of the tumor. In fact, in vitro studies showed that a high expression of MUC1 could 
lead to a lower cell to cell adhesion as well as adhesion between cells and  
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extracellular matrix [(Hilkens et al. 1995), (Wesseling et al. 1996), (Wesseling et al. 
1995)].  A higher MUC1 expression also results in contraction of collagen type I 
matrix and altered expression of epithelial cytokeratins (Hudson et al. 2001).  Taking 
these findings into account in addition to our previous observations of the pattern of 
expression of MUC1 in IMPCa we hypothesised in a previous publication on the 
subject that this pattern of expression “may be responsible at least in part, for the 
detachment of the cells from the stroma, one of the main entity-defining features of 
IMPCa” (Nassar et al. 2004). This finding also confirms the impression that IMPCa” is 
characterized by an abnormality in cell polarity that occurs in a fashion that is not 
seen in conventional carcinoma. In fact, in IMPCa the surface of the tumor cells that 
faces the stroma acquires apical secretory properties” (Nassar et al. 2004). In 
practice, immunohistochemical staining for MUC1 is used to confirm the diagnosis of 
invasive micropapillary carcinoma (Figure 4).  
 
Figure 4: MUC1 immunostaining in benign breast terminal duct-lobular units (left picture) and 
in invasive micropapillary carcinoma (right picture) both at 20x magnification. In the benign 
terminal duct-units, the staining is at the luminal surface of the benign glands whereas in 
invasive micropapillary carcinoma MUC1 stains the stroma-facing surface of the malignant 
cell clusters (Taken from Nassar et al. 2004).  
 
1.7. Aims of the study: extensive analysis of IMPCa at the clinical, 
immunohistochemical and molecular levels  
1.7.1. Aim 1: description of the features of IMPCa of the breast at our institute  
Our first aim is to provide a detailed description of IMPCa of the breast in our 
institute. The high yearly number (> 500) of newly diagnosed breast carcinomas at 
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the university hospital of Tuebingen allows us to get an overview of the frequency 
and characteristics of this relatively infrequent special type of breast cancer. More 
specifically we aim to characterise the morphology, expression of molecular markers, 
tumor behavior and outcome of the disease. There is to date no data on this type of 
breast cancer in the German population.   
1.7.2. Aim 2: Ancillary immunohistochemical parameters in IMPCa and classification 
into molecular subtypes 
Our second aim was to characterise IMPCa at the immunohistochemical level. These 
include studying 1) prognostic and predictive markers (hormone receptors, and Ki67-
proliferation index, p53 and PTEN) and according to some of these markers 
classifying the IMPCa in one of the four molecular subtypes, 2) markers used to 
further characterise this type of tumor and help in its differential diagnosis from 
metastases (GATA3)  
1.7.3. Aim 3: comparison of IMPCa to invasive carcinoma NST  
It is important to know if this type of tumor has in our patient population significantly 
different pathological characteristic and behavior as that of invasive breast 
carcinoma, no special type. 
1.7.4. Aim 4: molecular characteristics of IMPCa of the breast using next generation 
sequencing (NGS) 
Our last aim was to check if these tumors harbor genetic alterations affecting known 
oncogens or tumor suppressor genes. Identification of these mutations may be able 
to explain the morphology and behavior of IMPCa and ultimately check the possibility 
for targeted therapy in this aggressive type of tumor. For this purpose we selected 
cases with pure IMPCa  
1.8. Material and methods 
Institutional Review Board approval was obtained from the Universitätsklinikum 
Tübingen 
 
1.8.1. Patient cohort and clinicopathologic parameters 
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Breast cancer cases diagnosed at the Institute for Pathology at the University 
hospital of Tuebingen during the years 2003, 2004 and 2005 were reviewed. The 
study was limited to these three years in order to obtain a long-term follow-up. For 
the same reason i. e. the lack of reliable follow-up information, the cases referred 
from outside institutions (procedures that were performed outside the University 
Women’s Hospital in Tuebingen) were excluded. We collected all breast cancer 
cases, first diagnosis and recurrences, diagnosed within this period of time. A total of 
922 breast cancers were found. 
 
For each breast cancer case we reviewed the available H&E sections and collected 
relevant data from the pathology reports, the patients’ clinical electronic charts and 
cancer registry. After review of the sections we noted the morphological 
characteristics of the tumor including histological type (NST, special type or mixed), 
grade according to Ellston & Ellis, presence of lymphovascular invasion, presence of 
a DCIS component indicating if it is extensive, the latter being considered when DCIS 
constitutes more than 25% of the entire tumor mass. Tumor size, lymph node status, 
hormone receptors and HER2-oncoprotein status were collected from the pathology 
reports. All information regarding treatment (surgical procedure, endocrine, chemo, 
and radiation therapy) as well as follow-up data (local recurrence, distant metastases, 
and survival status) were obtained from the patients’ charts and the cancer registry.  
 
From this series, 43 cases of invasive carcinomas with predominant or focal 
micropapillary component were found. The specimens containing invasive 
micropapillary carcinoma consisted of resection specimens (excisional biopsies, 
simple mastectomies, modified radical mastectomies) and two needle core biopsies. 
Histologically, invasive micropapillary pattern was defined as first described by 
Siriaunkgul et al (Siriaunkgul and Tavassoli 1993). In addition to the parameters 
evaluated for all cases, we looked in these cases at the presence and type of the 
non-micropapillary invasive component. Lymphovascular invasion was considered to 
be present if tumor cells were found within a lymphatic space or a vessel in the 
stroma outside of the main tumor. Presence of micropapillary growth pattern was also 
assessed in axillary lymph node metastases.  
 
1.8.2. Tissue microarrays and immunohistochemical staining 
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On a subset of cases (IMPCa and non- IMPCa) we performed tissue microarray 
(TMA) in order to repeat the immunhistochemical staining for hormone receptors and 
HER2- oncoprotein. Other immune markers were also performed on the same TMAs 
(MIB1, p53, GATA3, androgen receptor, and PTEN).  
 
TMA was performed on randomly selected cases from the cohort. From each case 
we selected one or two tumor blocks and an additional block of non-involved breast 
tissue when the latter is not present on the tumor sections. TMA were manually 
constructed (BeecherInstruments MTA-1) from a total of 377 cases including 343 
surgical resections and 34 core biopsies. Among these, 27 cases had micropapillary 
morphology. Surgical resection specimens were represented by six 1mm-diameter 
spots, four from neoplastic and two from non-neoplastic breast tissue. Core biopsy 
cases were represented by 2-4 spots of tumor depending on the tumor amount.  
 
Immunohistochemical staining was performed using BenchMark XT IHC/ISH 
autostainer (Ventana Medical Systems, Roche; Tucson, Arizona). Briefly, 2.5μm 
sections were deparaffinised and subjected to heat-induced antigen retrieval using 
EDTA buffer (pH 8.4) for 64 minutes (standard CC1).Subsequently, incubation with 
the primary antibody (in the 37° temperature for 32 min) was followed by detection of 
reaction using iVIEW DAB (diaminobenzidine hydrochloride) v3 kit. All slides were 
counterstained with hematoxylin (4 min incubation). The sources, conditions and 
dilutions of the various antibodies used are as follows: ER (clone SP1 form Roche, 
rabbit monoclonal, ready to use), PR (1E2, form Roche, rabbit monoclonal, Ready to 
use), androgen receptor (AR441, form Dako, mouse monoclonal, dilution 1:200), 
HER2 (clone 4B5, from Roche, rabbit monoclonal, ready to use), Ki67 (clone MIB1, 
form Dako, mouse monoclonal, dilution 1:200), p53 (clone DO-7 form Novocastra, 
mouse monoclonal, dilution 1:200), GATA3 (clone L50-823 form Biocare, mouse 
monoclonal, dilution 1:500), and PTEN (clone 138G6, from Cell Signaling, rabbit 
monoclonal, 1:50). Fluorescent in situ hybridization (FISH HER2-Gen; Chromosom17 
PathVysion-Kit, Abbott-Molecular) was performed in cases where HER2 immunostain 
was equivocal (see below). For ER, PR, androgen receptor (AR), and GATA3 we 
noted semi-quantitatively the percentage of cells with nuclear staining and the 
intensity of staining (weak 1+, moderate 2+, strong 3+). The percentage of nuclear 
positivity was noted for MIB1 and p53. HER2 was scored as positive (3+), negative (0 
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or 1+) or equivocal (2+) according to the new ASCO/CAP criteria using IHC and FISH 
(when indicated i.e. in IHC 2+ cases) (reference). PTEN was score as negative (0 or 
1+ staining) or positive (2 or 3+ staining). The technical aspects of the 
immunohistochemical stains are summarised in Table 2. According to the 
immunhistochemical stains (ER, PR, HER2-Oncoprotein, and MIB1) we classified the 
tumors in one of the four molecular types (Luminal A, luminal B, HER2 and TN) 
according to the criteria described in the introduction.  
Table 2: Characteristics of the Antibodies used in the study    
 Clone Manufacturer Dilution Staining pattern 
ER SP1 Roche Ready to use Nuclear 
PR 1E2 Roche Ready to use Nuclear 
AR AR441 DAKO 1:200 Nuclear 
HER2 4B5 Roche Ready to use Membranous 
Ki67 MIB1 DAKO 1:200 Nuclear 
P53 DO-7 Novocastra 1:200 Nuclear 
GATA3 L50-823 Biocare 1:500 Nuclear 
PTEN 138G6 Cell Signaling 1:50 Cytoplasmic and nuclear 
 
 
1.8.3. Molecular studies using NGS 
Genomic DNA was extracted from 5 µm paraffin sections using the Maxwell® 16 
FFPE Tissue LEV DNA Purification Kit and the Maxwell® 16 Instrument (Promega, 
Madison, WI, USA) according to the manufacturer’s instructions. Isolated DNA was 
quantified using the Qubit® dsDNA HS Assay Kit (Thermo Fisher Scientific, Waltham, 
MA, USA). 
Targeted multigen mutation screening was performed by Next Generations 
Sequencing (Ion Torrent PGM, Thermo Fisher Scientific) using the AmpliSeq Cancer 
Hotspot Panel v2 (hotspot regions in 50 genes: ABL1, EZH2, JAK3, PTEN, AKT1, 
FBXW7, IDH2, PTPN11, ALK, FGFR1, KDR, RB1, APC, FGFR2, KIT, RET, ATM, 
FGFR3, KRAS, SMAD4, BRAF, FLT3, MET, SMARCB1, CDH1, GNA11, MLH1, 
SMO, CDKN2A, GNAS, MPL, SRC, CSF1R, GNAQ, NOTCH1, STK11, CTNNB1, 
HNF1A, NPM1, TP53, EGFR, HRAS, NRAS, VHL, ERBB2, IDH1, PDGFRA, ERBB4, 
JAK2, PIK3CA).  
In a primary step, the Ion AmpliSeq Library Kit v2.0 was applied to amplify hotspot 
target regions specified by the panel. Subsequently primer sequences were partially 
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digested using the FuPA reagent. Each sample was marked by barcodes ligating Ion 
Xpress™ Barcode Adapters which include sequencing adapters. Libraries were 
purified and quantified applying Agencourt AMPure XP (Beckman Coulter, Brea, 
CA, USA) magnetic beads and the Ion Library Quantitation Kit (Thermo Fisher 
Scientific) on the LightCycler 480 real-timer PCR system (Roche Molecular Systems, 
Pleasanton, CA, USA). Libraries were diluted to 100 pM each and pooled. In the next 
step DNA fragments were attached to Ion Sphere Particles (ISPs) and clonally 
amplified using the Ion PGM™ Hi-Q™ OT2 Kit and the Ion OneTouch™ Instrument. 
The amount of template-positive ISPs was determined with the Qubit 2.0 
Fluorometer and the Ion Sphere™ Quality Control Kit. Afterwards the Ion 
OneTouch™ ES was used to enrich template-positive ISPs. In a last step, 
sequencing primers were attached to the DNA fragments bound to the ISPs which 
were subsequently loaded on semiconductor chip (Ion 318™ Chip Kit). Finally 
sequencing was performed suing the the Ion PGM™ Hi-Q™ Sequencing Kit and the 
Ion Torrent PGM™ platform.  
Detection of non-synonymous variants compared to the human reference sequence 
(hg19) was performed using the Torrent Suite™ and the Ion Torrent Variant Caller. 
Detection thresholds were set at an allele frequency of 5%. Variants were annotated 
and filtered against the dbSNP and COSMIC databases using the Annotate variants 
single sample workflow of the Ion Reporter Software (Thermo Fisher Scientific). 
Obtained variants were further visualized with the freely available program Integrative 
Genomics Viewer (IGV, Broad Institute) to discriminate artefacts and true variants.  
 
1.8.4. Statistical analysis 
 
A comparison between IMPCa and IMPCa invasive carcinomas was performed. We 
compared the following clinicopathologic parameters: T stage, LN status, 
recurrence/metastases, and survival status. Since the majority of IMPC tumors were 
ER positive we limited the comparison to these cases with ER positive non-IMPC 
cases (n=186). Statistical analyses were performed using JMP 12.2.0 (SAS Institute, 
Cary, NC, USA). Categorical variables were compared with Pearson’s chi-square 
correlation calculated on contingency tables. Continuous variables were analyzed 
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using the Wilcoxon rank sum and chi-square test. A p value less than 0.05 was 
considered statistically significant. 
 
2. Results  
 
2.1. Description of the clinicopathological parameters of IMPCa of the breast:  
 
Cases of breast carcinoma with pure or partial micropapillary differentiation formed 
4.7% (43 patients) of the entire cohort of breast carcinomas diagnosed between 2003 
and 2005 at our institute. The women were aged between 31 and 87 years with a 
median age of 63 years. The majority of the patients were postmenopausal (90%). 
 
Histologically, in nine cases the tumor had pure micropapillary morphology (21%). In 
the other 34 cases, components of invasive carcinoma no special type (NST), lobular 
carcinoma or mucinous carcinoma were present; components from other special 
types of breast cancer were not observed. In two cases the NST component 
displayed a nested pattern reminiscent of neuroendocrine tumors. In a subset of 
cases (n=4; 9%) the tumor had at the same time mucinous and micropapillary 
morphology. Since according to literature (see introduction) those behave more like 
IMPCa than mucinous carcinoma, they were included in the IMPCa group of tumors. 
In these cases the micropapillae appear to be floating in mucin rather than being in 
empty spaces. Lymphovascular invasion (LVI) as defined in the material and 
methods was seen in 6 cases (14%). In regard to the Elston & Ellis tumor grade, 
almost all cases were G2; two cases displayed a G3 and one case was G1. A ductal 
carcinoma in situ (DCIS) component was seen in a quarter of the cases (n=11), being 
regarded as extensive in two of them. DCIS was typically intermediate grade with 
predominant micropapillary morphology. Of the 43 cases, 38 were first diagnosis 
tumors; in five cases (11.6%) the tumor represented a local recurrence of a primary 
carcinoma that was diagnosed between 1989 and 1996. For these five cases, the 
slides of the original tumors were not available for review and the original histology 
was unknown in the patients’ clinical history.  
 
The size of the tumors was available in 40 cases and varied between 0.5 to 4.5 cm 
with a mean size of 1.9 cm and a median of 2.0 cm. Pathologic T stage was 
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distributed as follows: 2.5% pT1a (n=1), 15% pT1b (n=6), 35% pT1c (n=14), 42.5% 
pT2 (n=17), 2.5% pT3 (n=1) and 2.5% pT4 (n=1). Multifocality/multicentricity was 
seen in 30% of the cases (n=12). These multifocal carcinomas belonged mostly to 
the pT2 stage followed by pT1c with one case staged as pT3. In regard to staging of 
the axilla, more than half of the patients (55%) had lymph nodes metastases. When 
the axillary lymph nodes were involved the number of positive nodes was more often 
greater than three. The distribution of axillary lymph nodes staging was as follows: 2 
cases pN1mic, 8 cases pN1a, 8 cases pN2a, and 3 cases pN3a. Less than half 
(44.5%) were node negative; there was no lymph node status available in nine 
cases. In the involved lymph nodes, the metastases exhibited micropapillary 
morphology at least focally.   
 
Information about treatment obtained from the patients’ charts and the Tuebingen 
cancer registry showed that 20 patients were treated with partial breast resection and 
20 had mastectomy either as initial procedure or after positive margins on an 
excisional biopsy. In addition, 38 patients had lymphadenectomy (88%). Regarding 
additional therapy, 27 patients received hormonal treatment, 26 patients underwent 
radiation therapy and 14 patients underwent chemotherapy. In other terms and for 
reasons that we were not able to identify 66% of the patients received endocrine 
therapy despite that 86% of them had positive hormone receptors. As far as 
combination of therapies, 12 patients were treated with radiation and endocrine 
therapy, seven patients had a combination of all three treatment modalities, five 
received endocrine therapy alone, 4 patients were radiated and had chemotherapy, 3 
patients were treated with radiation alone and 3 other patients received 
chemotherapy in addition to endocrine therapy. Seven of the patients did not receive 
any treatment besides surgery.  
 
Follow-up data was available in all but two patients (95%). Fifteen patients (15/41; 
36.5%) developed distant metastases either at presentation (2 patients) or after few 
months to 11 years of the breast cancer diagnosis. Four of these patients did not 
have any positive lymph nodes; one had a micrometases in one lymph node. In five 
cases there was no information on lymph nodes.  Eleven of the patients died from 
breast cancer between three to 10 years after the initial diagnosis.   
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2.2. Immunohistochemical staining  
  
2.2.1. Hormone receptors and HER2 oncoprotein 
 
Hormone receptors and HER2-oncoprotein status was available from the pathology 
reports for all patients. Thirty seven tumors were hormone receptor positive (86%). 
Among these three were also positive for HER2- oncoprotein. Four cancers were 
positive for HE2- oncoprotein and negative for hormone receptors (9.4%), two of 
them with a score of 2+ by immunohistochemistry and a detectable HER2 gene 
amplification by FISH. Two tumors were negative for all three markers (4.6%). Of 
note all the invasive carcinomas with pure micropapillary morphology were ER and 
PR positive without expression of HER2 oncoprotein.  
 
Immunostaining for ER, PR and HER2- oncoprotein was repeated on the TMA in 27 
cases of IMPCa. In general, there was no change of the hormone receptors status in 
any of the cases. For ER and HER2 the results did not differ from those retrieved 
from the pathology reports. For PR, the value was lower in five of the TMA cases in 
comparison to that seen in the reports staying within the positive range however 
(change from strongly positive in the reports to weakly positive in the TMA).  
 
Androgen receptor (AR) was negative in half of the cases that we were able to 
evaluate (13/26). The staining was weakly positive (in 5-10% of the tumor cells) in 
27% of the tumors (7 cases). The rest showed a positive labeling in >10% of the 
tumor cells, this labeling being diffuse only in a minority of cases (3 cases, 11%). All 
except two of the AR negative cases were ER positive, six of them with strong ER 
positivity. On the other hand the one IMPCa case that was ER negative (HER2 
positive) on TMA was also AR negative.  
 
2.2.2. Proliferation, p53 expression and PTEN  
 
The IMPCa expressed a low Ki-67 proliferation index (lower than 10%) in the vast 
majority of cases (89%). In three cases the value was greater than 15%, being 15%, 
20% and 30% in one case each.  P53 was not overexpressed in 85% of the cases. 
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Two cases of luminal B type and two cases of TN molecular type showed an 
expression of p53 of 20-50%. The expression of PTEN was lost in 42% of IMPCa. 
 
2.2.3. Expression of GATA3 
 
GATA3 was positive in 20 of 23 stained cases (87%) with a moderate to strong 
intensity and with a percentage of positive cells that varies from 30 to 100%. Of the 
cases that were negative for GATA3, two cases were also triple negative and one 
was negative for ER and PR but positive for HER2.  
 
2.2.4. Molecular classification 
 
With the use of the surrogate immunohistochemical staining (ER, PR, HER2 
oncoprotein, MIB1) we divided the cases into the four molecular subtypes using the 
recommendations of the saint Gallen consensus conference already mentioned in 
the Introduction. In the cases where no MIB1 staining was available we classified the 
cases based on the values of ER, PR and HER2 only. In summary, 55.6% (n=23) of 
the cases were luminal A, 21% (n=9) were luminal B-HER2 negative, 9.4% (n=4) 
were HER2 positive-luminal B, 9.4% (n=4) were HER2 type and 4.6% (n=2) were 
triple negative (TN) type.   
 
2.3. Molecular characteristics of selected pure IMPCa  
 
Using our 50 genes panel on six IMPCa cases with a pure invasive micropapillary 
component showed that three tumors were wild type for the genes tested and three 
others showed hotspot mutations.  
In one case we detected a missense mutation of the PIK3CA gene which affected a 
known Hotspot (c.3140 A>G) corresponding to the amino acid change p.H1047R. 
The allele frequency was 18%.  
In another case PIK3CA was wild type. A missense mutation of the TP53b gene 
(nucleotide change, c.637C>T and amino acid change p.R213) in addition to a 
mutation of the MET gene (nucleotide change, c.3029C>T and amino acid change 
p.T1010I) with a frequency of 33% and 35% respectively. 
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In the third case of the non-wild type IMPC a mutation of ABL1 gene was detected 
with a frequency of 48% affecting the c.797A>G and the amino acid p.K266R. The 
latter is believed to be a germline mutation.    
 
2.4. Comparison of IMPCa with invasive breast carcinoma NST 
 
As mentioned in the material and methods we compared the cases of IMPCa to the 
cases of invasive breast carcinomas NST in regard to staging (pT stage and lymph 
node status), risk of recurrence and distant metastases, survival, and the expression 
of specific immune markers. Since the majority of the IMPCa cases expressed ER, 
we limited the comparison to the ER positive tumors in both the IMPCa and the NST 
group. In other terms, at the molecular level the comparison was done between the 
luminal A and B cases in the IMPCa and the NST groups. The latter consisted of 219 
breast cancers.  
 
When comparing the stage at presentation, in our cohort, IMPC tumors had a 
statistically comparable pT stage distribution to that of NST breast cancers (pT 1mic 
+pT1a+ pT1b: 24%; pT1c: 41%, pT2: 31% and pT3 2% and pT4: 2%). Lymph nodes 
involvement however was overall significantly higher in IMPCa cases (p 0.02). 
   
The risks for distant metastases and /or local recurrence as well as the risk of death 
of disease were clearly higher in IMPC than in NST breast cancer cases. This 
occurred in 22% of the breast cancers with IMPCa whereas 11% of NST breast 
cancers recurred or displayed distant metastases (p < 0.0001). This difference is also 
statistically significant when matching for node status (p 0.005).  
 
We compared the distribution of the molecular subtypes (luminal A, luminal B-HER2 
negative, and luminal B-HER2 positive) in NST and IMPCa breast carcinomas. In 
both groups luminal A constituted the majority of the (ER positive) cases with 65% in 
IMPCa and 62% in NST. This was followed by luminal B-Her2 negative with 25 %and 
28% respectively. Luminal B-HER2 positive cases formed 10% of each category. 
This distribution did not show a statistically significant difference between the two 
categories.  
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At the immunohistochemical level, the expressions of p53 as well as the Ki67 
proliferation index were similar between the IMPCa and NST breast cancer cases. 
The expression of PTEN was lost in 42% of IMPCa and 37% of NST tumors, showing 
no statistically significant difference.  
 
3. Discussion 
3.1. Summary of the results 
The results of our study show that: 1) Invasive micropapillary morphology, which is 
seen in 90% of the cases in postmenopausal women, is not a very rare finding in 
breast cancer (approximately 5% overall). However, when present, it usually 
constitutes less than half of the tumor volume; pure invasive micropapillary 
carcinoma is seen only in one fifth of the cases. Regardless of extent, micropapillary 
differentiation is associated with a high rate of lymph nodes metastases and an 
aggressive behavior compared with invasive breast carcinoma NST. This confirms 
previous reports on this type of breast cancer in other patient populations. 2) The 
vast majority of the tumors belong to the luminal subtype with a high proportion of 
luminal B tumors. This distribution however was not different from that of the invasive 
carcinoma NST in our cohort. In addition and contrary to the findings in the literature 
Ki67 proliferation index was not higher in IMPCa. 3) A third of the pure IMPCa 
showed genetic alterations affecting TP53 or PIK3CA. 
3.2. Morphology of IMPCa of the breast and differential diagnosis 
3.2. 1. Morphological features  
As previously mentioned the majority of invasive micropapillary carcinomas in our 
series were admixed with invasive carcinoma NST. Less often however they were 
described in other reports to be admixed with other special subtypes of invasive 
breast cancer including tubular, papillary, mucinous or invasive lobular carcinoma 
[(Lopez-Beltran et al. 2010), (Pettinato et al. 2004), (Walsh and Bleiweiss 2001)]. 
When diagnosing a case of breast cancer where micropapillary features are noted, it 
is important to mention in the diagnosis the presence of any micropapillary 
component since even a minimal one can have negative prognostic implications. 
Ductal carcinoma in situ (DCIS) has been reported in 53% to 80% of the cases being 
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described as extensive in half of them [(Luna-More et al. 1994), (Middleton et al. 
1999), (Tressera et al. 1999), (Walsh and Bleiweiss 2001)]. DCIS is usually 
intermediate to high grade, often of micropapillary type but also cribriform or papillary 
types, with or without central necrosis (Figure 5). The identification of DCIS in a 
setting of IMPCa of the breast favours a primary carcinoma arising in this organ over 
metastases to the breast from IMPCa arising in other localisations, which can look 
identical.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: IMPCa of the breast in association with DCIS displaying micropapillary (picture to 
the left), cribriform and solid patterns with focal necrosis and microcalcifications (picture to 
the right), both at low magnification. 
 
3.2.2. Differential diagnosis 
3.2.2.1 Papillary carcinoma  
The term “papillary” describes an epithelial proliferation with fibrovascular cores 
where the apical surface of the neoplastic cells faces opposite to these cores. The 
term “micropapillary” is defined by a proliferation of neoplastic cells also with 
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reversed polarity of the secretory poles but without fibrovascular cores. Therefore 
IMPCa of the breast is not related to the special type of encapsulated papillary 
carcinoma of the breast. “The latter typically exhibits a complex arborescent growth 
pattern within cystically dilated spaces” (Fischer et al. 1980). This morphology is very 
different from the typical morphology of IMPCa. 
3.2.2.2. Mucinous carcinoma 
Mucinous carcinoma with micropapillary pattern has been described as a rare type of 
tumor exhibiting simultaneously mucinous and micropapillary features. Barbaschina 
et al emphasise the importance of recognising this tumor type in a paper where they 
described 15 cases of mucinous breast carcinoma (>90% mucinous pattern) with a 
micropapillary arrangement of the neoplastic cells. They showed that morphologically 
these tumors had intermediate to high nuclear grade, hobnail cells and frequent 
psammoma bodies. They were characterised by an aggressive behaviour relative to 
that of the usual type of mucinous carcinoma translated by a high frequency of 
lymphovascular invasion and lymph node metastases (Barbaschina et al. 2013). In 
the current series we came across four cases of invasive micropapillary mucinous 
carcinoma (9%) and included them in the IMPCa category (Figure 6).  
 
Figure 6: Mucinous carcinoma of the breast with micropapillary pattern 
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3.2.2.3. Retraction artefact 
Previous reports draw attention to the so-called retraction artefact in invasive breast 
cancer and describe it as occurring in association with a dense collagenous stroma 
and therefore should be differentiated from the clear spaces within the loose stroma 
of IMPCa. Retraction artefacts were assumed to be due to tissue fixation. In recent 
publications, Acs et al demonstrated that these are in fact not “artefacts “ of fixation 
but a real phenomenon that happens with certain breast cancers since they can be 
seen not only in resection specimens but also on frozen sections and on needle core 
biopsies [(Acs et al. 2007), (Acs et al. 2009)]. More importantly they reported that 
tumors with these areas of retraction have a larger size, a higher grade and a high 
frequency of lymph node metastases (Acs et al. 2012). Their findings were validated 
in a large prospective series of breast cancer cases where the extent of retraction 
correlated significantly with the above mentioned parameters as well as nodal 
metastases (Acs et al. 2014). Their extensive presence in a tumor predicted poor 
recurrence free survival and overall survival in node negative and node positive 
cases. They concluded therefore that retraction artefacts are a morphological 
translation of a biological change leading to frequent lymphovascular invasion and 
lymph node metastases even at an early stage. We assume from the description of 
their cases and the figures in the paper that IMPCa is included in this category i.e. 
the category of “breast carcinomas with extensive retraction clefts”, an opinion that 
might not be shared by other authors.  
3.2.2.4. Metastatic IMPCa to the breast from other organs 
Rarely metastases from other anatomic locations can occur in the breast. When 
these metastases originate from a tumor with a micropapillary component or a pure 
IMPCa they can manifest as IMPCa of the breast and the differential diagnosis 
between a metastases and a primary IMPCa of the breast can be difficult.  
Particularly challenging are metastases to the breast (or the axillary lymph nodes) 
from serous carcinomas of the peritoneum, ovary or fallopian tube, a possibility that 
should be kept in mind. In addition to clinical information, the morphological features 
of the tumor such as presence of DCIS and in some cases immunohistochemical 
stains can be helpful in this setting. Recine et al showed that the use of 
immunohistochemistry can help in the differential diagnosis; WT1 is usually 
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expressed in serous carcinomas arising in these organs but not in a breast primary 
(Recine et al. 2004). Lotan et al found that the best immunhistochemical panel to 
determine the primary site of IMPCa includes Uroplakin, CK20, TTF1, ER, WT1 
and/or PAX8, and mammaglobin (Lotan et al. 2009). IMPCa of lung is usually positive 
for TTF1 (and CK7) and negative for CK20 [(Amin et al. 2002), (Lotan et al. 2009)]. 
When the tumor is positive for Uroplakin and CK20 an urothelial origin can be favored 
[(Amin et al. 1994), (Lotan et al. 2009)]. Breast IMPCa is ER positive, mammaglobin 
positive, and PAX8/WT-1 negative, while ovarian carcinoma is ER positive, 
mammaglobin negative, and PAX8/WT-1 positive (Lotan et al. 2009). These studies 
were performed before the relatively recent widespread use of GATA3 as marker of 
breast origin. We found it to be positive in most of our cases and should be added to 
the above mentioned panels in the differential diagnosis. It is noteworthy that GATA3 
is also a marker of urothelial differentiation and hence is not helpful in differentiating 
an IMPCa of the breast from that of urothelial origin.  
3.3. Prognostic and predictive molecular features  
The majority of IMPCa are ER and PR positive with varying proportions according to 
different studies, reaching 100% in some studies [(Luna-More et al 1996), (Machió et 
al. 2009), (Marchió et al. 2008), (Paterakos et al. 1999), (Tressera et al. 1999), 
(Walsh and Bleiweiss 2001), (Yamaguchi et al. 2008)]. In our study the 86% of the 
cases were hormone receptor positive. A positive-HER2 expression has been 
demonstrated in 10 to 35% of cases. It is important to note that the ASCO/CAP 
recommends classifying as weakly positive or equivocal by immunohistochemisty 
(2+) carcinomas with circumferential intense and complete membranous staining in < 
10% of the tumor cells. IMPCa is an exception to this rule; in this tumor type a cup-
shaped intense staining and not a complete membranous staining is often seen and 
should be counted as positive (Wolff et al. 2014). Due to its hormone receptor 
positivity, IMPCa belongs in most cases to the luminal subtype of breast cancer. In 
addition it is characterized by a high Ki67 labeling index. According to Vingiani et al, 
in approximately 90% of these tumors the Ki67 labeling index is >14% and in two 
third of the cases >20% and therefore classified as luminal B (Vingiani et al. 2013). 
Marchio et al. demonstrated that the genomic changes in their series of IMPCa cases 
were similar to those described in the luminal B subtype. This was true for pure 
IMPCa as well as those admixed with invasive carcinoma NST [(Marchió et al. 2009), 
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(Marchió et al. 2008)]. The expression of basal markers (CK5/6, CK14, CK17, EGFR) 
in this tumor is extremely rare [(Kim et al. 2006), (Marchió et al. 2008), (Marchió et al. 
2009), (Weigelt et al. 2008)]. Our results are different than those reported and show 
that most IMPCa display a low proliferation index. Moreover the proportion of the 
luminal B cases, although relatively higher than that described for NST in the 
literature, was not different than that of the invasive carcinoma NST group in our 
series. The explanation could be that MIB1 immunostaining was performed on TMAs 
and therefore the tissue was not representative of the entire tumor. This is a problem 
with MIB1 since the hot spot areas should be reported. Our data show that p53 was 
not overexpressed in most of the cases. Like MIB1, it was high in the TN case.  
3.4 Clinical and radiological presentation   
At the clinical level, similar to invasive carcinoma NST, the most common 
manifestation of IMPCa is a palpable mass (60-94%), the rest being detected at 
screening mammography [(Adrada et al. 2009), (Günhan-Bilgen et al. 2002)]. 
Not many studies are available that extensively describe the radiological appearance 
of IMPCa of the breast. From these studies it appears that the radiological findings of 
IMPCa of the breast are not very specific. On mammography, these tumors typically 
appear as a high-density mass with spiculated margins that is often associated with 
microcalcifications. Microcalcifications with and without an associated mass or focal 
asymmetry were found in two thirds of the tumors in the study by Adrada et al. and in 
43% in the study by Günhan-Bilgen et al [(Adrada et al. 2009), (Günhan-Bilgen et al. 
2002)]. These microcalcifications are most likely associated with the accompanying 
DCIS component. Ultrasound studies usually reveal an irregularly shaped solid 
hypoechoic mass with indistinct margins without posterior acoustic shadowing or 
enhancement. Sonography is important in identifying lymph node metastases, it was 
able to identify approximately three quarters of axillary lymph nodes metastases in 
the same study (Adrada et al. 2009). MRI appearance of IMPCa was described in 
few cases  and is considered important for defining the extent of the disease, 
multifocality, and  tumor in the contralateral breast and therefore can play same as in 
invasive lobular carcinoma an important role in staging of the patient and subsequent 
disease management [(Adrada et al. 2009), (Lim et al. 2013)]. 
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3.5. Clinical behavior and survival 
Almost all studies describing IMPCa of the breast point that this tumor is 
characterized by a high degree of axillary lymph node involvement. For example, 
Luna-More et al. and Paterakos et al. reported 91% and 95% incidence of axillary 
node metastases respectively [(Luna-More et al. 1994), (Paterakos et al. 1999)]. 
When positive multiple lymph nodes are typically involved. We have shown in one 
series of IMPCa cases from a patient population treated in a tertiary health care 
centre in the USA that an average of six positive axillary nodes was detected. This 
number was even higher in the studies reported by Luna-More et al and Paterakos et 
al. (9.5 and 8.5 respectively) [(Luna-More et al. 2000), (Nassar et al. 2001), 
(Paterakos et al. 1999)]. Interestingly this high tendency for axillary nodal 
involvement is also described in relatively smaller tumors. It reaches 71% in T1 
tumors (Luna-More et al. 2000). According to Walsh and Bleiweiss, two third of the 
IMPCa lesions with a pT1b and 74% of lesions with pT1a tumor stage had positive 
regional lymph nodes (Walsh and Bleiweiss 2001). Similarly, in a recent study, 
Vigniani et al also showed that these tumors were characterized by a significantly 
higher frequency of axillary metastases than that observed with invasive breast 
carcinoma NST (69% versus 47%), and by a large proportion of node positive cases 
involving four or more lymph nodes (56% versus 36%) (Vingiani et al. 2013).  
As we pointed out in one of our previous publications on the topic, “it is possible that 
tumor foci with micropapillary growth pattern are a source of lymph node metastases, 
since examination of axillary contents revealed micropapillary differentiation in the 
lymph node tumor in most cases. It may be thus hypothesized that IMPCa represents 
an evolution of a subclone, acquiring a special morphology, and having a high 
propensity for regional lymphatic spread. This interpretation is further supported by 
the observation that foci of micropapillary growth were generally observed at the 
periphery (i.e., invasive growth front) of the primary tumor. The mechanism by which 
IMPCa facilitates nodal metastases is, at this point, unclear” (Nassar et al. 2001).  
The correlation between micropapillary morphology in breast cancer and an 
aggressive clinical behavior with worse survival is controversial. Paterakos et al., in 
their multivariate analysis of 21 cases of IMPCa failed to confirm that micropapillary 
phenotype predicted more aggressive clinical behaviour and a shortened disease 
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free or overall survival (Paterakos et al. 1999). In one of our previous studies we 
showed that although the overall outcome was worse for patients with the diagnosis 
of IMPCa in comparison to patients with invasive breast carcinoma NST, when 
matched for lymph node status however, survival appeared to be similar in both 
groups. We then postulated that “the high proportion of node positive patients with 
advanced metastatic tumor burden and skin involvement likely explains this 
difference and concluded that the outcome of a patient with IMPCa depends largely 
on staging parameters in a manner analogous to invasive breast carcinoma NST” 
(Nassar et al. 2001). This finding has been confirmed by Vigniani et al. In their study 
of 49 IMPCa cases with follow-up they showed that despite the unfavourable 
clinicopathologic characteristics of these tumors and the fact that they arise more 
often as locally advanced disease, the micropapillary morphology is not an 
independent risk factor for locoregional and distant disease recurrence or for overall 
survival (Vingiani et al. 2013). 
Our study demonstrates that in our patient population and similar to other populations 
of patients affected with breast cancer, lymph nodes involvement is significantly 
higher in IMPCa than in NST with a comparable stage at presentation. In addition the 
risk of local and distant recurrence is much higher than that in NST also when 
matching for nodal status.   
3.6. Pathogenesis of IMPCa 
3.6.1. Previous observations 
To date, the studies that attempted to explain the special morphology of IMPCa and 
its behavior have been able to show, using electron microscopy, special stains and 
immunostains, that the secretory surface of the neoplastic cells faces the stroma or 
more precisely the clear spaces between the cancer cell clusters and the stroma 
[(Luna-More et al. 1994), (Nassar et al. 2004)]. As we mentioned previously we 
demonstrated using immunohistochemistry that MUC1 glycoprotein, which is located 
in the apical surface of normal glandular cells, can be identified in IMPCa, in the 
stroma-facing surface of the neoplastic cells. Studies have shown that MUC1, 
because of its high molecular weight and chemical properties is believed, when 
highly expressed, to result in decreased cell to cell and cell to extracellular matrix as 
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well as contraction of collagen type I [(Hilkens et al. 1995), (Hudson et al. 2001), 
(Winterford et al. 1999), (Wesseling et al. 1995), (Wesseling et al. 1996)]. In light of 
these observations, one can assume that, by its localisation at the surface of the cell 
facing the stroma (reversed polarity) in IMPCa, MUC1 may be responsible for the 
detachment of the cells from the stroma and the appearance of clear spaces around 
the cell clusters, which is one of the defining morphologic characteristics of IMPCa. If 
this finding can to a certain extent explain the appearance of IMPCa, there is no clear 
explanation of how this special morphology correlates with an aggressive tumoral 
behavior.  
3.6.2. Genomic analysis of IMPCa of the breast  
Molecular and genetic studies have been done in an attempt to explain the 
characteristic morphology and aggressive behaviour of IMPCa. These studies were 
mainly conducted on tumors in breast. Thor et al. used comparative genomic 
hybridization on 16 cases of invasive micropapillary carcinomas and identified 
specific genomic patterns such as 8p losses, 8q gains and 17p and 16q losses much 
more frequently than in invasive carcinoma NST and invasive lobular carcinoma 
(Thor et al. 2002). A comparison done by Marchiò C et al between 24 IMPCa and a 
series of 48 grade and ER-matched invasive breast carcinoma NST revealed that 
high cyclin D1 expression, high proliferation rates, and MYC (8q24) amplification 
were significantly associated with the former (Maranchie et al. 2000). They also 
demonstrated a striking genetic and immunohistochemical similarity between pure 
IMPCas and those mixed with invasive breast carcinoma NST regardless of the 
amount of the invasive micropapillary component (Marchiò et al. 2009). This finding 
might explain the aggressive behaviour of tumors even with a minor micropapillary 
component.  They showed in addition an amplification of the chromosome 8p11.2-
p12 in four of 12 mixed tumors, a region that harbours interesting therapeutic target 
candidates, such as FGFR1 and PPAPDC1B (Marchiò et al. 2009).  
One of the most recent studies of the genetic alterations in IMPCa was published by 
Gruel et al. The authors report the following observations:  1) “unsupervised analysis 
of genomic data distinguishes two IMPCa subsets, the first exhibiting a significant 
increase in 16p gains (71%), and the other characterised by a high frequency of 8q 
(35%), 17q (20% to 46%) and 20q (23% to 30%) amplifications and 17p loss (74%)”  
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2) “compared to invasive carcinoma NST, IMPCa exhibits specific loss of the 6q16-
q22 region (45%), which is associated with downregulation of FOXO3 and SEC63 
gene expression” and 3) “by using whole-exome sequencing combined with RNA 
sequencing of these tumors they identified in rare cases somatic mutations in genes 
involved in polarity, DNAH9 and FMN2 (8% and 2%, respectively) or ciliogenesis, 
BBS12 and BBS9 (2% each) or genes coding for endoplasmic reticulum protein, 
HSP90B1 and SPTLC3 (2% each) and cytoskeleton, UBR4 and PTPN21 (2% each), 
regardless of the genomic subset” (Gruel et al. 2014). These genetic alterations 
alone cannot explain the pattern of IMPCa and its behavior since they were not 
observed in all cases. Therefore the authors raise the possibility that other biological 
alterations (for example, epigenetic modifications, stromal alterations) could also play 
a significant role in this process. In another study Natrajan et al demonstrated that 
IMPCa is not defined by highly recurrent mutations or by recurrent fusion gene 
(Natrajan et al. 2014). 
In the current study we performed NGS on six pure IMPCa of the breast. Most of 
these cases did not show any mutation of the 50 genes included in our panel.  In two 
cases (one third of the total), mutations of the TP53 and PIK3CA genes were 
detected, each in one case. A mutation of the MET gene (MET-T1010I) was seen in 
the tumor with TP53 gene mutation. The presence of activating point mutations in 
IMPCa of the breast was also addressed in a study by Flatley et al. The authors 
identified Hotspot point mutations in 35% of IMPCa including PIK3CA exons 7, 9 und 
20 Hotspots as well as the AKT1 plekstrin homology domain mutation (E17K); 
mutations in TP53 and KRAS were each found in 5% of the cases. They concluded 
that the rate of PIK3CA mutation in their series was similar to that described for 
invasive carcinoma NST but noted that there might be enrichment of AKT mutations 
in IMPCa (Flatley et al. 2013).  
In breast cancer, TP53 gene mutations are the second most commonly observed 
genetic alterations -mutations in the PIK3CA gene are the most frequent- being 
detected in 30% of the cases. Their distribution correlates significantly with the 
molecular subtype; they are found in 26% of luminal A and B tumors, 50% of HER2 
and 88% of basal like subtypes (Gui et al. 2016). In the two latter subtypes the 
mutations are usually complex whereas base pair substitutions occur in the luminal 
type similar to that seen in our IMPCa series. On the other hand, MET-T1010I 
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germline mutation is very rare in breast cancer occurring in approximately 2% of 
patients with metastatic breast cancer. It has been shown that “overexpression of 
wild type MET (MET-WT) as well as expression of MET-T1010I increases colony 
formation, cell migration and invasion in-vitro and tumor growth in-vivo. Moreover, in 
comparison to MET-WT, MET-T1010I appears to selectively impact cell invasion and 
therefore, according to the authors, it should be considered in the clinical trials of 
MET inhibitors (Liu et al. 2015). In light of these observations, MET-T1010I mutation 
in one of our IMPCa cases is of interest in potentially explaining the aggressive 
behavior of IMPCa since it is mostly seen in metastatic breast cancer and in offering 
targeted therapy to patients with tumors harboring this mutation. The numbers in our 
series are too small to be able to draw definite conclusions. It is therefore important 
to specifically look for this mutation in a larger series of IMPCa of the breast.  
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4. Summary 
Invasive micropapillary morphology is associated with clinically meaningful staging 
and outcome implications in patients with breast cancer. The characteristic 
micropapillary morphology is seen focally in the tumor in most cases. In contrast to 
other special subtypes of breast cancer, any proportion of invasive micropapillary 
growth confers to the tumor a “special” aggressive behaviour characterised by 
lymphovascular invasion, high propensity for lymph node metastases and high stage 
at presentation. At the molecular and immunohistochemical level, tumors with mixed 
invasive micropapillary and invasive carcinoma NST display striking similarities to 
those with pure invasive micropapillary carcinomas. Moreover, these tumors are 
classified in most cases in the category of luminal B molecular subtype.  
Invasive micropapillary carcinoma has been described in other organ systems, 
although less frequently as in breast. In the urinary tract, gastrointestinal tract, lungs 
and salivary glands, this tumor pattern is in general admixed with a more 
conventional tumor growth pattern, and same as in breast, presents as a locally 
advanced disease and is associated with an aggressive behaviour.  
To date there are few molecular studies performed on IMPCa of the breast. None of 
them shows characteristic genetic alteration that could explain the special 
morphology of the tumor or its aggressive course. In other terms, IMPCa is not 
defined by highly recurrent specific mutations or fusion genes. In few cases reported 
in the literature as well as in the study that we presented, hotspot point mutations of 
the PIK3CA gene, and the TP53 gene were identified however at a rate similar to that 
seen in invasive breast carcinoma NST. In addition we saw in one of our IMPCa 
cases a MET-T1010I germline mutation, which is usually very rare in breast cancer, 
occurring in 2% of patients with metastatic breast carcinoma. Because of the 
therapeutic consequences (with MET inhibitors) we suggest a more extensive testing 
of the MET gene in this aggressive type of breast cancer. 
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Zusammenfassung 
Mikropapilläre Morphologie des invasiven Mammakarzinoms hat bedeutende 
Konsequenzen für Brustkrebs Patientinnen, da sie Einfluss auf Staging und 
Prognose nehmen. In den meisten Fällen ist das mikropapilläre Wuchsmuster ein 
Teil des Tumors und tritt mit anderen Subtypen des Mammakarzinoms gemischt auf. 
Im Gegenteil zu anderen speziellen Typen ist jeder mikropapilläre Anteil im Tumor 
mit einem aggressiveren Verhalten assoziiert, beispielweise Lymphangioinvasion, 
Lymphknotenmetastasen und fortgeschrittenem Tumorstadium. Auf molekularer und 
immunhistochemischer Ebene verhalten sich die gemischten IMPCa und NST 
Tumoren verglichen mit den reinen IMPCa sehr ähnlich. In den meisten Fällen 
gehören diese Tumoren zu den molekularen Luminal B Syptypen. 
IMPCa wurden bereits in anderen Organen beschrieben, allerdings nicht so häufig 
wie in der Mamma. Bei Neoplasien des Harn- und Gastrointestinaltrakts, der Lungen 
oder der Speicheldrüsen tritt das mikropapilläre Wuchsmuster auch mit 
konventionellen Karzinomtypen gemischt auf. Ebenso wie bei Mammakarzinomen 
präsentieren sich diese Tumoren in lokal fortgeschrittenem Tumorstadium und sind 
mit einem aggressiveren Verhalten assoziiert. 
Bis jetzt sind nur wenige molekulare Studien zu IMPCa der Mamma durchgeführt 
worden. Keine dieser Studien konnte bislang weder die spezielle Morphologie noch 
das aggressive Verhalten erklären. Zudem kann das IMPCa der Mamma den Studien 
zufolge nicht über hoch repetitive spezifische Mutationen oder Genfusionen definiert 
werden.  
In wenigen Fällen sowie in unserer Studie wurden Punktmutationen der PIK3CA- und 
TP53-Gene gefunden, doch mit der gleichen Häufigkeit wie in NST 
Mammakarzinomen. Zusätzlich konnten wir eine MET-T1010l Keimbahnmutation 
beweisen, welche normalerweise sehr selten in Mammakarzinomen vorkommt und 
zwar in durchschnittlich 2% der metastasierten Tumoren. Aufgrund der daraus 
resultierenden Therapiemöglichkeiten (MET-Inhibitoren) wäre ein ausführlicheres 
Testen in Hinblick auf das MET-Gen in IMPCa der Mamma ratsam. 
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